Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Employees

627

Sector

Biotechnology & Medical Research

Calendar

02-24 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/12/25	25.40 $	+1.32%	2,406,872
09/12/25	25.07 $	-2.83%	1,513,649
08/12/25	25.80 $	+1.38%	1,300,476
05/12/25	25.45 $	+0.75%	1,275,494
04/12/25	25.26 $	-1.44%	1,884,419

Delayed Quote Nyse, December 10, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.40USD

Average target price

33.22USD

Spread / Average Target

+30.80%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:02 10/12/2025 GMT			5-day change	1st Jan Change
25.40 ^USD	+1.32%		-0.90%	+70.58%

12-03	Arcus Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 10:30 AM
11-03	Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating	MT

Capitalization	3.14B 2.7B 2.52B 2.36B 4.35B 282B 4.73B 29.26B 11.4B 134B 11.79B 11.54B 491B	P/E ratio 2025 *	-7.19x	P/E ratio 2026 *	-6x
Enterprise value	2.54B 2.18B 2.04B 1.9B 3.51B 228B 3.82B 23.61B 9.2B 108B 9.52B 9.32B 397B	EV / Sales 2025 *	10.7x	EV / Sales 2026 *	19.4x
Free-Float	59.4%	Yield 2025 *	-	Yield 2026 *	-

12-03	Arcus Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 10:30 AM
11-03	Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating	MT
10-31	Arcus Biosciences Prices $250 Million Common Stock Offering	MT
10-31	Arcus Biosciences says it announces pricing of $250 million public offering of common stock	RE
10-30	Arcus Biosciences Insider Sold Shares Worth $2,010,578, According to a Recent SEC Filing	MT
10-29	Wedbush Raises Price Target on Arcus Biosciences to $35 From $33, Keeps Outperform Rating	MT
10-28	Arcus Biosciences reports third-quarter 2025 financial results and provides a pipeline update	RE
10-28	Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q3 Revenue $26.0M, vs. FactSet Est of $21.0M	MT
10-28	Cancer drug developer Arcus Biosciences' Q3 net loss widens	RE
10-28	Arcus Biosciences, Inc. Provides Earnings Guidance for the Full Year 2025	CI
10-28	Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-20	Taiho Pharmaceutical Co., Ltd. and Arcus Biosciences, Inc. Exercises Option for an Exclusive License to Cas Datifan in Japan and Certain Territories in Asia	CI
10-14	Arcus Biosciences, Inc. Announces First Overall Survival Results from Arm A1 of the Phase 2 EDGE-Gastric Study	CI

11-03	Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating	MT
10-29	Wedbush Raises Price Target on Arcus Biosciences to $35 From $33, Keeps Outperform Rating	MT
10-14	Arcus Biosciences, Inc. Announces First Overall Survival Results from Arm A1 of the Phase 2 EDGE-Gastric Study	CI
10-07	Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating	MT
08-18	Mizuho Raises Price Target on Arcus Biosciences to $45 From $42, Keeps Outperform Rating	MT

Arcus Biosciences, Inc. Share Price

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Valuation: Arcus Biosciences, Inc.

Chart: Arcus Biosciences, Inc.

Latest news: Arcus Biosciences, Inc.

Last Transcript: Arcus Biosciences, Inc.

Analysts' recommendations: Arcus Biosciences, Inc.

Press Releases: Arcus Biosciences, Inc.

News in other languages: Arcus Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arcus Biosciences, Inc.

ETFs: Arcus Biosciences, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-09	Arcus Biosciences Announces New Employment Inducement Grants	BU
11-18	Arcus Biosciences to Participate in Two Upcoming Investor Conferences	BU
10-31	Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock	BU
10-30	Arcus Biosciences Announces Commencement of Public Offering of Common Stock	BU
10-28	Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update	BU

03/10/24	Borsa di Italia: Un ingannevole ritorno alla calma
03/10/24	Bolsa de Madrid: Un engañoso retorno a la calma
03/10/24	En Direct des Marchés : TotalEnergies montre ses muscles, LVMH en F1, Casino maigrit
03/10/24	Un retour au calme en trompe l'œil
30/01/24	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	+1.32%
1 week	-0.90%
Current month	-2.68%
1 month	+30.52%
3 months	+116.72%
6 months	+153.49%
Current year	+70.58%

1 week	24.67	26.4
1 month	19.33	26.4
Current year	6.5	26.4
1 year	6.5	26.4
3 years	6.5	34.93
5 years	6.5	49.1
10 years	6.3	49.1

Manager	Title	Age	Since
Juan Jaen PSD	President	68	30/04/2015
Terry Rosen CEO	Chief Executive Officer	67	30/04/2015
Robert Goeltz DFI	Director of Finance/CFO	53	31/07/2020

Director	Title	Age	Since
Terry Rosen CHM	Chairman	67	30/11/2017
Kathryn Falberg BRD	Director/Board Member	65	17/09/2017
Yasunori Kaneko BRD	Director/Board Member	71	30/04/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARCUS BIOSCIENCES, INC.	+1.32%	-0.90%	+45.81%	-16.42%	3.14B
LONZA GROUP AG	-0.70%	-2.85%	+2.79%	+17.60%	47.04B
IQVIA HOLDINGS INC.	+2.23%	-1.90%	+9.70%	+6.90%	37.96B
BEONE MEDICINES AG	+1.25%	-4.49%	+72.10%	+63.80%	35.71B
CELLTRION, INC.	-0.85%	+1.31%	+11.36%	+16.84%	27.64B
MEDPACE HOLDINGS, INC.	+3.06%	-2.73%	+63.99%	+172.51%	15.8B
REVOLUTION MEDICINES, INC.	+0.09%	+0.24%	+64.69%	+227.50%	15.06B
ICON PUBLIC LIMITED COMPANY	+2.52%	-1.02%	-13.94%	-4.57%	14.19B
TEMPUS AI, INC.	-1.07%	+0.21%	+66.82%	-	13.36B
IONIS PHARMACEUTICALS, INC.	-0.29%	-3.92%	+105.51%	+109.68%	12.74B
Average	+1.02%	-1.57%	+42.88%	+65.98%	22.26B
Weighted average by Cap.	+0.81%	-1.90%	+33.94%	+53.83%

	2025 *	2026 *
Net sales	238M 204M 191M 179M 330M 21.4B 359M 2.22B 864M 10.15B 894M 875M 37.23B	129M 111M 103M 96.6M 178M 11.58B 194M 1.2B 467M 5.49B 483M 473M 20.14B
Net income	-366M -314M -294M -275M -507M -32.9B -551M -3.41B -1.33B -15.59B -1.37B -1.34B -57.23B	-460M -395M -369M -345M -637M -41.34B -693M -4.28B -1.67B -19.6B -1.73B -1.69B -71.92B
Net Debt	-606M -521M -487M -455M -839M -54.5B -913M -5.65B -2.2B -25.83B -2.28B -2.23B -94.81B	-639M -549M -513M -480M -885M -57.46B -963M -5.95B -2.32B -27.23B -2.4B -2.35B -99.95B